As of November 7, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of First Tracks Biotherapeutics Inc. The largest reported stake is Fmr LLC's, at 15%. 8 filings are on record since April 22, 2026 (Schedule 13G/A, November 6, 2026).
Sell to companies like First Tracks Biotherapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 6,302,482 · Shared voting: 0 · Sole dispositive: 6,302,672 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-06
- · Reporting person: BlackRock, Inc. · Sole voting: 2,499,954 · Shared voting: 0 · Sole dispositive: 2,558,473 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: TCG Crossover GP II, LLC · Sole voting: 0 · Shared voting: 1,447,652 · Sole dispositive: 0 · Shared dispositive: 1,447,652 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 2,495,777 · Sole dispositive: 0 · Shared dispositive: 2,495,777 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Affinity Asset Advisors, LLC · Sole voting: 2,032,012 · Shared voting: 0 · Sole dispositive: 2,032,012 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-13
First Tracks Biotherapeutics Inc has 8 Schedule 13D or 13G filings on record since 2026-04-22. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15% | 6,302,672 | SCHEDULE 13G/A, 2026-11-06 | 2026-10-30 |
| EcoR1 Capital, LLC | 9.1% | 3,174,519 | SCHEDULE 13G, 2026-04-22 | 2026-04-20 |
| 8.3% | 2,895,304 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 | |
| BlackRock, Inc. | 7.2% | 2,558,473 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| Sirenia Capital Management LP | 7.2% | 2,495,777 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Affinity Asset Advisors, LLC | 5.8% | 2,032,012 | SCHEDULE 13G, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind First Tracks Biotherapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on First Tracks Biotherapeutics Inc and the records around it.
First Tracks Biotherapeutics Inc elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
Watch First Tracks Biotherapeutics Inc
Get an email when First Tracks Biotherapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on First Tracks Biotherapeutics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on First Tracks Biotherapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on First Tracks Biotherapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 6,302,482 | 0 | 6,302,672 | 0 | SCHEDULE 13G/A, 2026-11-06 |
| Abigail P. Johnson | 0 | 0 | 6,302,672 | 0 | SCHEDULE 13G/A, 2026-11-06 |
| TCG Crossover GP II, LLC | 0 | 1,447,652 | 0 | 1,447,652 | SCHEDULE 13G, 2026-08-14 |
| TCG Crossover Fund II, L.P. | 0 | 1,447,652 | 0 | 1,447,652 | SCHEDULE 13G, 2026-08-14 |
| TCG Crossover GP III, LLC | 0 | 1,447,652 | 0 | 1,447,652 | SCHEDULE 13G, 2026-08-14 |
| TCG Crossover Fund III, L.P. | 0 | 1,447,652 | 0 | 1,447,652 | SCHEDULE 13G, 2026-08-14 |
| Chen Yu | 0 | 2,895,304 | 0 | 2,895,304 | SCHEDULE 13G, 2026-08-14 |
| BlackRock, Inc. | 2,499,954 | 0 | 2,558,473 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| Sirenia Capital Management LP | 0 | 2,495,777 | 0 | 2,495,777 | SCHEDULE 13G, 2026-08-14 |
| Alex Silverstein | 0 | 2,495,777 | 0 | 2,495,777 | SCHEDULE 13G, 2026-08-14 |
| Affinity Asset Advisors, LLC | 2,032,012 | 0 | 2,032,012 | 0 | SCHEDULE 13G, 2026-08-13 |
| Michael Cho | 2,032,012 | 0 | 2,032,012 | 0 | SCHEDULE 13G, 2026-08-13 |
The latest filing identifies First Tracks Biotherapeutics Inc by CUSIP 337185102 and gives its principal executive office as 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA 92121 (SCHEDULE 13G/A, 2026-11-06).
What the percentages are based on
As of June 30, 2026, the Reporting Persons beneficially own approximately 5.8% of the Common Stock outstanding The percentages disclosed above are based on 34,892,381 shares of Common Stock of the Issuer outstanding as of May 12, 2026, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 14, 2026.Affinity Asset Advisors, LLC, SCHEDULE 13G, 2026-08-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-22 | EcoR1 Capital, LLC | 9.1% | SCHEDULE 13G |
| 2026-07-28 | BlackRock, Inc. | 5.5% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 5.9% | SCHEDULE 13G |
| 2026-08-13 | Affinity Asset Advisors, LLC | 5.8% | SCHEDULE 13G |
| 2026-08-14 | Sirenia Capital Management LP | 7.2% | SCHEDULE 13G |
| 2026-08-14 | Chen Yu | 8.3% | SCHEDULE 13G |
| 2026-10-27 | BlackRock, Inc. | 7.2% | SCHEDULE 13G/A |
| 2026-11-06 | Fmr LLC | 15% | SCHEDULE 13G/A |
Questions about who owns First Tracks Biotherapeutics Inc
Who owns First Tracks Biotherapeutics Inc?
On this page, 6 holders' latest ownership filings report 5% or more of First Tracks Biotherapeutics Inc: Fmr LLC (15%, Schedule 13G/A, filed 2026-11-06), EcoR1 Capital, LLC (9.1%, Schedule 13G, filed 2026-04-22), Chen Yu (8.3%, Schedule 13G, filed 2026-08-14), BlackRock, Inc. (7.2%, Schedule 13G/A, filed 2026-10-27) and Sirenia Capital Management LP (7.2%, Schedule 13G, filed 2026-08-14); 1 more is listed above.
Who are the largest shareholders of First Tracks Biotherapeutics Inc?
By the share each holder's latest filing reports, the largest holders of First Tracks Biotherapeutics Inc on this page are Fmr LLC (15%), EcoR1 Capital, LLC (9.1%) and Chen Yu (8.3%).
When did Fmr LLC buy into First Tracks Biotherapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-08-06, reporting 5.9%; its latest, Schedule 13G/A filed 2026-11-06, reports 15%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for First Tracks Biotherapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 20, 2026 | Leadership change: Ajim Tamboli appointed, Chief Financial Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for First Tracks Biotherapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.